Computational Modeling Of Injection-Related Tissue Responses In Drug Delivery

By Olivia Jefferies, Junior Device Development Engineering Student, Oval Medical Technologies, Elizabeth Margerison, PhD, Marketing Manager, Oval Medical Technologies, and Asmita Khanolkar, Senior Director, Cambridge Pharma, SMC

At the global level, the trends continue to move medical care from hospital to homes and the need for at home care for both chronic diseases as well as crisis life-threatening diseases. This is leading to further growth areas for autoinjectors to deliver drugs and biologic products. The autoinjectors have usability advantages over other drug delivery methods, such as manual injections. Autoinjectors can enhance safety, improve dosing accuracy, and improve patient compliance especially in self-administration settings. With this significant growth, research is necessary to understand the relationship between body morphology, injection force and needle length. This can help to improve both the patient experience and the effectiveness of the devices.

Oval Medical Technologies offers a variety of autoinjector technology platforms with both subcutaneous and intramuscular capabilities to deliver a wide range of challenging novel drug formulations with high viscosities and a wide range of delivered volumes. With challenging novel formulations, complex molecules, large dosage and new delivery sites, optimizing delivery along with the formulation is the key for successful clinical outcomes.